£7.8M
The Cambridge-based synthetic gene provider raised the capital from Mercia Ventures to expand operations and develop its DNA synthesis platform.
CB
Camena Bioscience
Camena Bioscience develops enzyme-based DNA synthesis technology for the life sciences sector.
Cambridge, UK—Founded 2016
£7.8MTotal raised
Camena Bioscience provides synthetic genes to the pharmaceutical and biotechnology sectors through its proprietary enzyme-based platform. The firm supplies accurate DNA sequences to support disease research and drug discovery programmes.
Categories
Founders
SH
Steve Harvey
CEO
Steve is the chief product officer and co-founder of Camena Bioscience, having previously worked as a scientist at the Wellcome Trust Sanger Institute.
LinkedIn
Derek Stemple
CSO
Derek serves as chief science officer and co-founder at Camena Bioscience, following research and investigator roles at the Wellcome Trust Sanger Institute and the National Institute for Medical Research.
LinkedInInvestors
